Kathy Wilson, MD
Pulmonary Disease · Conover, NCNPI 1114095841
Payments from drug & device makers
Across 228 payments — averaging $57.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Actelion Pharmaceuticals US, Inc.$1K
- GSK$579
- Boehringer Ingelheim$369
- Inspire Medical Systems, Inc.$209
- Philips North America LLC$146
- plus $1K from 31 others
What the payments were for
- Speaking & faculty fees$8,17563%
- Travel & lodging$600%
- Food & beverage$4,76937%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $9,113 |
| Actelion Pharmaceuticals US, Inc. | 44 | $1,123 |
| GSK | 25 | $579 |
| Boehringer Ingelheim | 23 | $369 |
| Inspire Medical Systems, Inc. | 5 | $209 |
| Philips North America LLC | 9 | $146 |
| Regeneron Healthcare Solutions, Inc. | 6 | $127 |
| Mylan Specialty L.p. | 8 | $119 |
| Harmony Biosciences LLC | 4 | $101 |
| Sunovion Pharmaceuticals Inc. | 8 | $93 |
| Amgen | 5 | $89 |
| AbbVie(2 entities) | 4 | $82 |
| Insmed, Inc. | 3 | $64 |
| United Therapeutics Corporation | 3 | $61 |
| Baxter Healthcare | 3 | $60 |
| Sanofi | 3 | $58 |
| Paratek Pharmaceuticals, Inc. | 3 | $56 |
| Mallinckrodt Enterprises LLC | 3 | $53 |
| Mallinckrodt Hospital Products Inc. | 2 | $43 |
| Portola Pharmaceuticals, LLC | 3 | $41 |
| Genentech USA, Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Merck | 2 | $37 |
| Electromed, Inc. | 2 | $35 |
| Nuwellis, Inc. | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 2 | $32 |
| Viatris Specialty LLC | 1 | $28 |
| Novo Nordisk | 1 | $27 |
| Gilead | 1 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $23 |
| Inogen, Inc. | 1 | $18 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Pfizer | 1 | $13 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,020 in reported general payments places this provider in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $284,437 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $88,829 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 89 | $66,409 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $21,003 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $16,620 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $13,062 |
| EliquisApixaban | 12 | $6,940 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,592 |
| Atrovent HfaIpratropium Bromide | 11 | $5,211 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,095 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 194 | $4,906 |
| Ventolin HfaAlbuterol Sulfate | 51 | $2,837 |
| Azithromycin | 110 | $883 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $649 |
| Montelukast Sodium | 48 | $483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $369 | $290,02934 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $579 | $126,452187 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $9,113 | $84,566152 claims |
| PfizerEliquis | $13 | $6,94012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Conover
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
- Lake MorrisonDurham$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.